💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Imprimis says no prescriptions received for two patients who died after receiving curcumin emulsion

Published 08/07/2017, 11:44 AM
© Reuters.  Imprimis says no prescriptions received for two patients who died after receiving curcumin emulsion
HROW
-
  • Imprimis Pharmaceuticals (IMMY -8.4%) says the it did not receive prescription orders nor did it dispense any product to the two patients who died recently who, according to the FDA, received its curcumin emulsion.
  • It says both cases appear to be situations where the medical provider wrote a prescription for one patient, but used it in another.
  • The company adds that it tested the IV bag from the 30-year old patient and found no drugs or poisons, including DEG, above 0.1% by volume, thereby not supporting the claim that DEG or PEG 40 Castor Oil caused the death.
  • Shares were down almost 19% before recovering.
  • Previously: Imprimis down 18% of FDA inquiry into compounded product (Aug. 4)
  • Now read: Is This Gilead's Takeover Target?


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.